Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
+0.23 (0.22%)
After Hours: 104.76 0.00 (0.00%)
Nov 24, 4:23PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 102.22 - 104.89
52 week 71.14 - 140.00
Open 103.57
Vol / Avg. 317,817.00/931,382.00
Mkt cap 8.71B
P/E     -
Div/yield     -
EPS -2.65
Shares 84.74M
Beta 2.34
Inst. own 79%
Feb 10, 2016
Q4 2015 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 9, 2015
Alnylam Pharmaceuticals Inc at Oppenheimer Healthcare Conference - 1:35PM EST - Add to calendar
Dec 2, 2015
Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 12:30PM EST - Add to calendar
Nov 18, 2015
Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 11, 2015
Medicines Co and Alnylam Conference Call to Discuss ALN-PCSsc Results at American Heart Association (AHA) Scientific Sessions
Nov 10, 2015
Alnylam Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 9, 2015
Q3 2015 Alnylam Pharmaceuticals Inc Earnings Release
Nov 9, 2015
Q3 2015 Alnylam Pharmaceuticals Inc Earnings Call
Nov 3, 2015
Alnylam Pharmaceuticals Inc RNAi Roundtable: Treatment of Transthyretin-Mediated Amyloidosis
Sep 30, 2015
Alnylam Pharmaceuticals Inc at Leerink Partners Rare Disease Roundtable
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1214.30% -712.79%
Operating margin -1238.62% -800.97%
EBITD margin - -777.39%
Return on average assets -20.76% -48.05%
Return on average equity -22.56% -59.74%
Employees 256 -
CDP Score - -


300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company’s pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Officers and directors

John K. Clarke Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President - General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
David-Alexandre Gros Senior Vice President, Chief Business Officer
Age: 42
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 40
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 56
Bio & Compensation  - Reuters
Amy W. Schulman Director
Age: 54
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters